( SAN CARLOS Calif.--(BUSINESS WIRE)--Ap...)Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice,with Transplant of Purified Donor Blood Stem Cells,Health

SAN CARLOS, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - Cellerant Therapeutics today announced the publication of data suggesting that established autoimmune disease can be reversed or stabilized by the transplantation of purified allogeneic (donated) hematopoietic (blood forming) stem cells (HSC) in a mouse study of Systemic Lupus Erythematosus (SLE). Subjects that underwent this procedure exhibited improved overall survival and decreased lupus symptoms. The research, led by Dr. Julie Christensen with colleagues from Cellerant and Stanford University, was published on April 13, 2007 as a First Edition Paper in the online version of the American Society of Hematology's journal, BLOOD (Smith-Berdan et. al., DOI 10.1182/BLOOD-2007-03-081497).

"The demonstration of successful reversal of the disease using purified stem cells with non-myeloablative conditioning offers a novel strategy to treat autoimmune diseases such as lupus with decreased morbidity," said Ramkumar Mandalam, Ph.D., Vice President of Pharmaceutical Operations. "This study also provides further support for our belief that purified stem cells may make it possible to use un-matched donors, such as a parent or non-identical sibling, for a variety of HSC treatment procedures."

"The publication of this preclinical data further validate Cellerant's unique use of pure hematopoietic stem cells for a wide range of therapeutic applications, including lupus and other autoimmune disorders, as well as for cancer and blood disorders," commented Bruce Cohen, Cellerant's President and CEO. "This finding is consistent with recent reports on successful use of hematopoietic stem cell transplantation for the treatment of autoimmune diseases and merits evaluation of pure stem cells in treating such diseases."

Cellerant researchers worked with specialized mice that are prone to an autoimmune condition that closely resembles human SLE. The study evaluated both
'"/>

Page: 1 2 3
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care